Repligen (RGEN) Tops Q3 EPS by 14c, Raises FY Guidance

Go back to Repligen (RGEN) Tops Q3 EPS by 14c, Raises FY Guidance

Repligen Reports Third Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance

October 28, 2021 7:30 AM EDT

Reports record revenue of $178.2 million for the quarter, representing year-over-year growth of 89% and organic growth of 77%Raises revenue guidance to $655-$665 million for full year 2021Completes acquisition of affinity ligands innovator Avitide Inc.

WALTHAM, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter of 2021. Provided in this press release are financial highlights for the three- and nine- month periods ended September 30, 2021, updates to our... More